Plain-English translation of NCT06055439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CHM-2101, a personalized immune therapy designed to fight certain gastrointestinal cancers that have stopped responding to standard treatments. The treatment works by taking some of your own immune cells, modifying them in a laboratory to recognize and attack cancer cells, and then putting them back into your body. This is one of the first studies testing whether this approach is safe and effective for people with advanced stomach, colon, rectal, or neuroendocrine cancers.
Standard chemotherapy and other treatments don't work for everyone with advanced gastrointestinal cancers, and some patients' cancers come back after initial treatment. This medication represents a new approach—using your own immune system as a personalized weapon against cancer—and researchers want to see if it can help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll first undergo a procedure called leukapheresis, where doctors collect some of your white blood cells through a needle in your arm (similar to donating blood). Those cells are then sent to a laboratory where they're modified and grown to create your personalized treatment. While the cells are being prepared, you may receive additional chemotherapy to keep your cancer stable. Once your cells are ready, you'll receive chemotherapy to prepare your body, followed by an infusion of your modified cells. You'll then be followed closely for 18 months with regular visits and tests to monitor how well the treatment is working and any side effects you experience.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States